Abhijit “Ron” Mazumder joins as Partner  
Lisa Alderson joins as Entrepreneur in Residence 

January 24, 2023

Illumina Ventures, a genomics and precision health focused venture firm, today announced additions to its investment team. Abhijit “Ron” Mazumder, PhD, MBA, joins as a Partner and Lisa Alderson, MBA as an Entrepreneur in Residence. 

 

Ron brings almost thirty years of experience working with biomarkers, technologies, and computational approaches for pharmaceutical and diagnostics programs. After leading the development of genomics technologies and novel platforms for several biotech companies, Ron worked for Johnson and Johnson and Merck, where he developed diagnostics and companion diagnostics, pharmacodynamic and predictive biomarkers. Most recently, Ron was Vice President and Global Head of Oncology Biomarker Development and Companion Diagnostics at Genentech.  

​ 

“We are fortunate to expand our bench of talent with the addition of Lisa and Ron,” said Nick Naclerio, PhD, Illumina Ventures Founding Partner. “These two new members will bring a wealth of knowledge and experience to help us continue to support innovation in genomics and precision medicine.” 

 

Lisa has more than twenty-five years of experience creating and scaling innovative, high-growth businesses at the intersection of technology and healthcare with a focus on genomics, digital health, SaaS, telehealth, and molecular diagnostics. She is a mission-driven founder, board member, and advisor dedicated to improving patient care and advancing the adoption of precision medicine. Lisa co-founded and served as CEO of Genome Medical, the leading telehealth provider of genomics-based care to patients nationwide. She also served as Chief Commercial Officer and Chief Strategy Officer at Invitae, a genetic information and molecular diagnostics company, where she led the commercial organization through initial commercial launch, scale-up, and IPO. 

​

About Illumina Ventures

Illumina Ventures is an independently managed, healthcare-focused venture firm in a strategic partnership with Illumina, with the vision to unlock the power of the genome. As an early-stage, value-add investor, Illumina Ventures helps entrepreneurs develop breakthrough science and technologies into market-leading companies to transform healthcare. The firm focuses on investment in life science tools, therapeutics, diagnostics, and personal wellness.

For more information, visit illuminaventures.com.